ImmunityBio
IBRX
39 hedge funds and large institutions have $6.57M invested in ImmunityBio in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 14 closing their positions.
2% more capital invested
Capital invested by funds: $6.47M → $6.57M (+$98.7K)
0.94% less ownership
Funds ownership: 6.42% → 5.48% (-0.94%)
17% less funds holding
Funds holding: 47 → 39 (-8)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
75% less call options, than puts
Call options by funds: $13K | Put options by funds: $53K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$124K |
| 2 |
Renaissance Technologies
New York
|
+$103K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$57.9K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$57.7K |
| 5 |
Bank of New York Mellon
New York
|
+$39.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$518K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$269K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$127K |
| 4 |
Jane Street
New York
|
-$92K |
| 5 |
WCM
Wildcat Capital Management
New York
|
-$80K |
IBRX Hedge Fund Activity: Q3 2019 in Review
39 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2019, worth a combined $6.57M — up 1.5% from $6.47M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IBRX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $124K. The largest seller was Millennium Management, cutting an estimated $518K.
- 39 institutional investors held ImmunityBio (IBRX) as of Q3 2019, down from 47 in Q2 2019.
- Funds reported $6.57M of ImmunityBio stock for Q3 2019, up 1.5% quarter-over-quarter.
- 6 funds opened new ImmunityBio positions in Q3 2019 and 14 closed out, a net change of -8 holders.
- The largest ImmunityBio buyer in Q3 2019 was Vanguard Group, an estimated $124K added.
- The largest ImmunityBio seller in Q3 2019 was Millennium Management, an estimated $518K sold.
Based on aggregated 13F filings for Q3 2019.